Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Utah Medical Products (UTMD) Research & Development (2016 - 2025)

Utah Medical Products has reported Research & Development over the past 16 years, most recently at $212000.0 for Q4 2025.

  • Quarterly results put Research & Development at $212000.0 for Q4 2025, up 75.21% from a year ago — trailing twelve months through Dec 2025 was $668000.0 (down 17.94% YoY), and the annual figure for FY2025 was $668000.0, down 17.84%.
  • Research & Development for Q4 2025 was $212000.0 at Utah Medical Products, up from $167000.0 in the prior quarter.
  • Over the last five years, Research & Development for UTMD hit a ceiling of $266000.0 in Q1 2024 and a floor of $112000.0 in Q3 2022.
  • Median Research & Development over the past 5 years was $136500.0 (2022), compared with a mean of $153100.0.
  • Biggest five-year swings in Research & Development: skyrocketed 91.73% in 2024 and later crashed 47.06% in 2025.
  • Utah Medical Products' Research & Development stood at $141000.0 in 2021, then fell by 12.77% to $123000.0 in 2022, then rose by 18.7% to $146000.0 in 2023, then fell by 17.12% to $121000.0 in 2024, then surged by 75.21% to $212000.0 in 2025.
  • The last three reported values for Research & Development were $212000.0 (Q4 2025), $167000.0 (Q3 2025), and $135000.0 (Q2 2025) per Business Quant data.